A pharmacist care program: positive impact on cardiac risk in patients with type 2 diabetes.

abstract：PURPOSE:It is known that selective cyclooxygenase 2(COX-2) inhibitors increase mortality in patients with previous myocardial infarction, and it has been suggested that COX-2 plays an important role in cardioprotection against ischemia. The current study was carried out to determine whether COX-2 is involved in the mec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Tosaka S,Tosaka R,Matsumoto S,Maekawa T,Cho S,Sumikawa K

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:Renalase is a protein that can regulate sympathetic nerve activity by metabolizing catecholamines, while redundant catecholamines are thought to contribute to atherosclerosis (As). Catecholamine release can be facilitated by angiotensin (Ang) II by binding to Ang II type 1 (AT1) receptors. Valsartan, a speci...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Zhou M,Ma C,Liu W,Liu H,Wang N,Kang Q,Li P

更新日期：2015-09-01 00:00:00

abstract：:We present two patients who were diagnosed with symptomatic sinus node dysfunction in the setting of hypercalcemia secondary to hyperparathyroidism. An extensive review of the literature has not revealed previous reports of this pathologic process. ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Shah AP,Lopez A,Wachsner RY,Meymandi SK,El-Bialy AK,Ichiuji AM

更新日期：2004-06-01 00:00:00

abstract：:Catestatin (CST), which is emerging as a novel cardiac modulator, can protect the heart against excessive sympathetic drive in hypertensive cardiomyopathy. The aim of this study is to investigate whether exogenous CST decreases excessive cardiac sympathetic drive and improves autonomic function and exerts cardioprotec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wang D,Liu T,Shi S,Li R,Shan Y,Huang Y,Hu D,Huang C

更新日期：2016-11-01 00:00:00

abstract：BACKGROUND:epidemiologic studies indicate that elevated heart rate (HR) is an independent risk factor for mortality and morbidity in patients (pts) with chronic heart failure (CHF). Clinical trials with β-blockers suggest that HR reduction is an important mechanism of their benefit in pts with stable CHF. Pharmacologic...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sarullo FM,Fazio G,Puccio D,Fasullo S,Paterna S,Novo S,Di Pasquale P

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) were recently shown to be capable of electromechanical integration following direct injection into intact or recently injured guinea pig hearts, and hESC-CM transplantation in recently injured hearts correlated with improvements in contractile funct...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Shiba Y,Filice D,Fernandes S,Minami E,Dupras SK,Biber BV,Trinh P,Hirota Y,Gold JD,Viswanathan M,Laflamme MA

更新日期：2014-07-01 00:00:00

abstract：INTRODUCTION:Limited data exist comparing the efficacy and safety of bumetanide- or metolazone-based diuretic regimens to furosemide in acute heart failure (HF). Our purpose was to evaluate the comparative effect on urine output (UO) and renal function between these regimens. METHODS:A retrospective study of hospitali...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ng TM,Konopka E,Hyderi AF,Hshieh S,Tsuji Y,Kim BJ,Han SY,Phan DH,Jeng AI,Lou M,Elkayam U

更新日期：2013-07-01 00:00:00

abstract：:BACKGROUND: In recent years, there has been an increasing use of antiarrhythmic drugs that act predominantly by prolonging myocardial repolarization. An inevitable electrophysiologic consequence of these drugs is the development of torsade de pointes as a proarrhythmic reaction. Both intravenous lidocaine and magnesiu...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Takanaka C,Ogunyankin KO,Sarma JS,Singh BN

更新日期：1997-04-01 00:00:00

abstract：:BACKGROUND: The tendency for the electrophysiologic effect of class III antiarrhythmic agents (action potential prolongation) to be diminished at faster heart rates represents a major drawback of this class of drug and is usually referred to as "reverse use dependence." A novel class III agent, MS-551, has recently be...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Nakaya Y,Martin DK,Campbell TJ

更新日期：1997-01-01 00:00:00

abstract：BACKGROUND:In recent decades, clinical trials have played an increasingly important role in determining how we practice. Trial results proving that a clinical finding poses risk have led to interventions that try to reduce risk. Clinical trials proving that a particular therapy provides better outcome than another ther...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Reiffel JA

更新日期：2000-01-01 00:00:00

abstract：:BACKGROUND: The effectiveness of antisense oligodeoxynucleotides for in vitro and in vivo studies is limited by a low efficiency of cellular uptake and instability due to degradation by nucleases. To overcome some of these problems, we recently developed a transfer method that utilizes inactivated Sendai virus (hemagg...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Morishita R,Gibbons GH,Horiuchi M,Nakajima M,Ellison KE,Lee W,Kaneda Y,Ogihara T,Dzau VJ

更新日期：1997-07-01 00:00:00

abstract：:The primary effect of ischemia is reduced aerobic adenosine triphosphate (ATP) formation in mitochondria. This triggers accelerated glycolysis and reduced cell pH, Ca(2+) accumulation, K(+) efflux, adenosine formation, and the clinical signs of ischemia: chest pain and a shift in the ST segment. Traditional therapies ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Stanley WC

更新日期：2004-09-01 00:00:00

abstract：:A large body of evidence indicates that a persistently high heart rate is associated with a significant risk for higher mortality and sudden death in individuals with a variety cardiovascular disorders, as well as in the general population. Heart rates elevated beyond a certain threshold have been found to be a risk f...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh N

更新日期：2002-04-01 00:00:00

abstract：:Phosphodiesterase inhibitors as inodilators in heart failure are associated with promotion of arrhythmias. Calcium sensitizers have been proposed for the treatment of severe decompensated heart failure. The effect of levosimendan, a calcium sensitizer, and milrinone, a phosphodiesterase inhibitor, on ventricular arrhy...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Papp JG,Pollesello P,Varró AF,Végh AS

更新日期：2006-06-01 00:00:00

abstract：PURPOSE:Methotrexate is an anti-inflammatory drug that has been shown to have anti-ischemic effects. Our aim was to evaluate if methotrexate could reduce infarct size in patients with ST-segment elevation myocardial infarction (STEMI). METHODS:We randomly assigned patients with STEMI to receive either methotrexate or ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Moreira DM,Lueneberg ME,da Silva RL,Fattah T,Gottschall CAM

更新日期：2017-11-01 00:00:00

abstract：BACKGROUND:Congestion predominates in exacerbations of heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF), but evidence suggests that excess volume may be distributed differently in these 2 subgroups. METHODS AND RESULTS:In this retrospective study, diuretic efficiency (DE, or ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Broscious R,Kukin A,Noel ZR,Devabhakthuni S,Seung H,Ramani GV,Reed BN

更新日期：2021-03-01 00:00:00

abstract：OBJECTIVE:To describe major events at follow up in octogenarian patients with atrial fibrillation (AF) according to anticoagulant treatment: direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs). METHODS:A total of 578 anticoagulated patients aged ≥80 years with AF were included in a prospective, obse...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ortiz MR,Muñiz J,Esteve-Pastor MA,Marín F,Roldán I,Cequier A,Martínez-Sellés M,Saldivar HG,Bertomeu V,Anguita M

更新日期：2020-07-01 00:00:00

abstract：INTRODUCTION:Angiotensin converting enzyme inhibitors (ACEIs) are widely prescribed medications. A recent British study reported a 14% increased risk of lung cancer with ACEI versus angiotensin receptor blocker (ARB) prescriptions, and risk increased with longer use. We sought to validate this observation. METHODS:We ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Anderson JL,Knowlton KU,Muhlestein JB,Bair TL,Le VT,Horne BD

更新日期：2021-01-29 00:00:00

abstract：BACKGROUND AND OBJECTIVES:Myocardial hypertrophy is a common clinical finding leading to heart failure and sudden death. Mitofusin 2 (Mfn2), a hyperplasia suppressor protein, is downregulated in hypertrophic heart. This study examined the role of Mfn2 in myocardial hypertrophy and its potential signal pathway. METHODS...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Yu H,Guo Y,Mi L,Wang X,Li L,Gao W

更新日期：2011-06-01 00:00:00

abstract：BACKGROUND:Published data indicated that combination use of clopidogrel and proton pump inhibitors (PPIs) may increase the incidence of major adverse cardiovascular events (MACEs). This has been a highly controversial topic for years. DESIGN:The present study was performed to evaluate whether combination therapy of cl...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Niu Q,Wang Z,Zhang Y,Wang J,Zhang P,Wang C,Yin X,Hou Y

更新日期：2017-03-01 00:00:00

abstract：:Dofetilide is a class III antiarrhythmic agent approved by the Food and Drug Administration for the conversion of atrial fibrillation and atrial flutter and maintenance of sinus rhythm in symptomatic patients with persistent arrhythmia. Drug trials showed neutral mortality in post-myocardial infarction patients and th...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Wolbrette DL,Hussain S,Maraj I,Naccarelli GV

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Mortality after acute myocardial ischemia has been reduced by aspirin (ASA) but mechanisms other than the antiplatelet effect have not been established. This article evaluates an antiarrhythmic action during sympathetic stimulation in the intact anesthetized dog with and without ischemia. METHODS AND RESULT...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Shehadeh AA,Arena J,Moschos CB,Regan TJ

更新日期：2000-04-01 00:00:00

abstract：BACKGROUND:The administration of aspirin is traditionally discontinued prior to coronary artery bypass grafting (CABG), given a potential risk of excessive postoperative bleeding. Few studies have previously suggested the benefits of continuing aspirin until the time of surgery. The primary aim of this review is to eva...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Ma X,Ma C,Yun Y,Zhang Q,Zheng X

更新日期：2014-01-01 00:00:00

abstract：:Cardiovascular diseases are one of the most common causes of death in humans and are responsible for billions of dollars in health care expenditures. As the molecular basis of cardiac diseases continues to be explored, there remains the hope for identification of more effective therapeutics. MicroRNAs (miRNAs) are rec...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Calway T,Kim GH

更新日期：2015-03-01 00:00:00

abstract：:BACKGROUND: The effects of sotalol on the 24-hour profile of the QT interval relative to that of the heart rate (HR) may be helpful in determining the time course of the drug's action in controlling cardiac arhythmias. This has not been previously determined. Thus, the objective of the current study was to evaluate th...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sharma PP,Sarma JS,Singh BN

更新日期：1999-01-01 00:00:00

abstract：:Beta-Adrenergic blockers have a wide spectrum of action for controlling cardiac arrhythmias that is larger than initially thought. Data from the past several decades indicate that, as an antiarrhythmic class, beta-blockers remain among the very few pharmacologic agents that reduce the incidence of sudden cardiac death...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Singh BN

更新日期：2005-06-01 00:00:00

abstract：BACKGROUND:Allogeneic cardiosphere-derived cells (CDCs) exert cardioprotective effects when administered intracoronarily after reperfusion in animal models of acute myocardial infarction (AMI). The "no-reflow" phenomenon develops rapidly post-reperfusion and may undermine the efficacy of cell therapy, due to poor cell ...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Sousonis V,Sfakianaki T,Ntalianis A,Nanas I,Kontogiannis C,Aravantinos D,Kapelios C,Katsaros L,Nana M,Sampaziotis D,Sanoudou D,Papalois A,Malliaras K

更新日期：2021-01-01 00:00:00

abstract：:Postischemic accumulation of intracellular Na+ promotes calcium overload and contributes to cellular necrosis. Cardioprotection afforded by pharmacologic blockade of the sodium-hydrogen exchanger subtype 1 (NHE1) is thought to be more remarkable than that obtained by ischemic conditioning (IC). The window of protectio...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Kingma JG

更新日期：2018-05-01 00:00:00

abstract：:BACKGROUND: Nicotine, the active agent in tobacco, is released into the circulation during cigarette smoking. It elevates plasma catecholamines, heart rate, and arterial blood pressure; produces coronary spasm; and increases myocardial work and oxygen demand with concomitant reduction in oxygen supply. This may genera...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Mehta MC,Jain AC,Mehta A,Billie M

更新日期：1997-10-01 00:00:00

abstract：BACKGROUND:Low levels of 25-hydroxyvitamin D (25(OH)VitD) have been recognized as an emerging cardiovascular disease (CVD) risk factor. Statins are reported to increase 25(OH)VitD concentration. Animal studies suggest that ezetimibe is a moderate inhibitor of intestinal 25(OH)VitD absorption, but its effect in humans i...

journal_title：Journal of cardiovascular pharmacology and therapeutics

authors： Liberopoulos EN,Makariou SE,Moutzouri E,Kostapanos MS,Challa A,Elisaf M

更新日期：2013-05-01 00:00:00